Robert W. Baird analyst Brian Skorney maintained a Hold rating on Regeneron (REGN – Research Report) on October 22 and set a price target ...

To request a FREE 2-week trial subscription, please signup. NOTE - this can take up to 48hrs to be approved.

This webinar explores how immersing yourself in the patient experience can add measurable, actionable value to your approach ...

Amgen's move follows the lifting of a temporary injunction on the launch of its Pavblu-branded biosimilar by the US Court of ...

Amgen AMGN will report third-quarter 2024 results on Oct. 30, after market close. In the last reported quarter, the company ...

By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...

John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on Regeneron (REGN – Research Report). The associated price ...

With “nerves of steel,” Amgen is getting ready to sell a copycat of Regeneron’s top-selling eye drug Eylea, even as ...

Wall Street opened lower on Wednesday, with key indices reflecting cautious sentiment among investors amid a number of ...

Novo Nordisk asked the FDA to bar compounding pharmacies from making semaglutide, arguing it is too complex for the ...

There is a lack of understanding among neurologists on how to balance the risks for and benefits of corticosteroids in ...

Me CEO Anne Wojcicki continues to maintain a strong outlook despite recent high-profile stumbles. “We are a long-term company ...